Pharmalittle: Highlights from Recent Developments in Medicine
Biogen has shared mixed findings from a mid-stage trial for an Alzheimer’s treatment aimed at the tau protein, amidst other industry news.
Editorial Staff
1 min read
Updated 7 days ago
Recent reports indicate that Biogen has released mixed results from a mid-stage clinical trial focused on a treatment for Alzheimer’s disease targeting the tau protein.
In addition to Biogen's updates, there are notable developments in the pharmaceutical sector, including layoffs at Takeda.
These events reflect ongoing challenges and advancements within the medical field, as companies navigate the complexities of drug development and market dynamics.